Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Mirum Pharmaceuticals Inc shares valued at $580,000 were purchased by JOLANDA MARIE HOWE on Aug 07 ’25. At $58.00 per share, JOLANDA MARIE HOWE acquired 10,000 shares.
Also, CHRISTOPHER PEETZ purchased 40,000 shares, netting a total of over 2,210,040 in proceeds.
Before that, Howe Jolanda had sold 564 shares from its account. In a trade valued at $27,213, the SVP, GLOBAL CONTROLLER traded Mirum Pharmaceuticals Inc shares for $48.25 each. Upon closing the transaction, the insider’s holdings decreased to 564 shares, worth approximately $0.17 million.
Analysts at Stifel started covering the stock with ‘”a Buy”‘ outlook in a report released in mid April. As of December 18, 2023, H.C. Wainwright has reiterated its “Buy” rating for MIRM.
Analyzing MIRM Stock Performance
On last trading session, Mirum Pharmaceuticals Inc [NASDAQ: MIRM] rose 12.04% to $59.82. The stock’s lowest price that day was $54.745, but it reached a high of $61.0 in the same session. During the last five days, there has been a surge of approximately 15.75%. Over the course of the year, Mirum Pharmaceuticals Inc shares have jumped approximately 55.38%.
Is Mirum Pharmaceuticals Inc subject to short interest?
Stocks of Mirum Pharmaceuticals Inc saw a sharp rise in short interest on 2025-07-15 jumping by 0.36 million shares to 6.58 million. Data from Yahoo Finance shows that the short interest on 2025-06-13 was 6.22 million shares. A jump of 5.51% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 13.85 of the overall float, the days-to-cover ratio (short ratio) jumped to 13.85.
Which companies own the most shares of Mirum Pharmaceuticals Inc (MIRM)?
In terms of Mirum Pharmaceuticals Inc share price expectations, FactSet research, analysts set an average price target of 59.5 in the next 12 months, up nearly 11.44% from the previous closing price of $53.39. Analysts anticipate Mirum Pharmaceuticals Inc stock to reach 75 by 2025, with the lowest price target being 39. In spite of this, 9 analysts ranked Mirum Pharmaceuticals Inc stock as Buy at the end of 2025. On November 13, 2023, Morgan Stanley assigned a price target of “an Overweight” to the stock and initiated coverage with a $60.
